Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index increased by 0.22% as of May 8, 2025, with notable gains from stocks such as Borui Pharmaceutical (+6.22%) and Maiwei Biotech (+3.68%) [1] - The Sci-Tech Pharmaceutical Index ETF (588700) rose by 0.42%, and over the past month, it has accumulated a 9.37% increase, ranking first among comparable funds [1] - The trading volume for the Sci-Tech Pharmaceutical Index ETF was 10.82 million CNY, with a turnover rate of 3.98% [3] Group 2 - The Sci-Tech Pharmaceutical Index ETF saw a significant growth in scale, increasing by 22.06 million CNY over the past two weeks, and its shares grew by 22.50 million [3] - The ETF experienced continuous net inflows over four days, with a peak single-day net inflow of 9.73 million CNY, totaling 26.61 million CNY [3] - As of April 30, 2025, the top ten weighted stocks in the index accounted for 53.3% of the total, including companies like United Imaging Healthcare and BeiGene [3] Group 3 - The biopharmaceutical industry maintained stable performance in Q1 2025, with 368 out of 371 listed companies reporting a total revenue of 280.68 billion CNY, a year-on-year decrease of 9.18%, and a net profit of 37.84 billion CNY [3] - The focus for investment in the pharmaceutical sector remains on innovative drug development, with an emphasis on leading companies in overseas markets and those combining innovative and generic drugs [3] - Investors without stock accounts can access the Sci-Tech Biopharmaceutical ETF linked fund (021061) for exposure to the sector [4]

（一）重要市场新闻 1、当地时间5月7日，美联储最新的联邦公开市场委员会货币政策会议纪要显示，美联储决定将联邦基 金利率目标区间继续维持在4.25%至4.5%之间。这是今年1月以来美联储连续第三次维持利率不变。美 联储鲍威尔会后再次重申，联储不急于行动，不认为应该先发制人降息应对关税冲击。他也表示，新关 税的水平远超美联储的预期。 2、美股三大指数集体收涨，道指涨0.7%，标普500指数涨0.43%，纳指涨0.27%，谷歌跌超7%，苹果跌 超1%，此前有消息称苹果正在"积极考虑"对其设备上的浏览器进行重大改版，重点转向以AI驱动的搜 索引擎，这一决定或将终结苹果与谷歌之间长达多年的合作关系，对谷歌在搜索领域的主导地位构成挑 战。中概股多数下跌，纳斯达克中国金龙指数跌2.34%。 3、国际油价走弱，美油主力合约收跌1.93%，报57.95美元/桶；布伦特原油主力合约跌1.91%，报60.96 美元/桶。国际金价走低，现货黄金跌1.95%，报3364.07美元/盎司；COMEX黄金期货跌1.47%，报 3372.60美元/盎司；COMEX白银期货跌2.31%，报32.61美元/盎司。欧洲三大股指收盘全线下跌，德国 ...

(本版专题数据由证券时报中心数据库提供) 内需市场一头连着经济发展，一头连着社会民生，是经济发展的重要依托。 2025年政府工作报告将"大力提振消费、提高投资效益，全方位扩大国内需求"列为今年政府工作十项任 务之首，并围绕"大力提振消费"作出了具体工作部署，提出要"实施提振消费专项行动，制定提升消费 能力、增加优质供给、改善消费环境专项措施，释放多样化、差异化消费潜力，推动消费提质升级"。 今年以来，一系列扩内需促消费政策发力显效，做强国内大循环，进一步释放我国超大规模市场活力。 在一季度实现"开门红"后，多地抓紧部署二季度经济工作重点，明确进一步聚焦提振内需，加快释放政 策效能。 广东明确，大力提振消费需求，深入实施提振消费专项行动，推动消费品以旧换新政策惠及领域进一步 延伸拓展，持续放大撬动效应；适度加大消费补贴和政府采购力度，促进广货国货消费、新型消费、入 境消费、公共消费等，不断挖掘消费增量，激发消费活力。 紧随其后的是达仁堂（600329），滚动市盈率为10.3倍。公司2024年归母净利润为22.3亿元，同比增长 125.94%，拟向全体股东每10股派发现金红利12.80元(含税)。市盈率较低的还有 ...

Core Viewpoint - The AI Fund Morgan Healthcare Stock A (001766) reported a profit of 56.7046 million yuan for Q1 2025, with a weighted average profit per fund share of 0.1457 yuan, and a net asset value growth rate of 11.84% during the reporting period [2]. Fund Performance - As of April 24, the fund's net asset value growth rates were as follows: 11.85% over the last three months, 7.74% over the last six months, 9.35% over the last year, and -22.62% over the last three years, ranking 30/54, 18/54, 23/54, and 34/46 among comparable funds respectively [3]. - The fund's Sharpe ratio over the last three years was -0.2714, ranking 36/44 among comparable funds [8]. - The maximum drawdown over the last three years was 48.16%, with the largest single-quarter drawdown occurring in Q1 2021 at 27.96% [10]. Fund Holdings and Strategy - The fund had an average stock position of 84.34% over the last three years, with a peak of 92.01% at the end of Q1 2025 and a low of 77.64% at the end of Q3 2021 [13]. - As of the end of Q1 2025, the fund's total assets amounted to 530 million yuan [14]. - The fund has a high concentration of holdings, with the top ten positions including companies such as Aier Eye Hospital, Zai Lab, and Hengrui Medicine [17]. Management Commentary - The fund manager indicated a strong belief in the value creation potential of innovative drug and device companies that leverage China's engineering and scientific talent, leading to significant investments in globally competitive firms [2].

Group 1 - The core viewpoint is that Noratech Biotech has benefited from the growth in the weight loss drug market, with over 60% of its revenue coming from overseas in 2024 [1][2] - The company reported a revenue of 1.625 billion yuan in 2024, representing a year-on-year growth of 57.21%, and a net profit of 404 million yuan, up 148.19% year-on-year [2] - Noratech Biotech is focusing on expanding its production capacity and entering emerging markets such as Southeast Asia, South America, and Russia to meet the high demand for peptide raw materials [2] Group 2 - The company has implemented several strategies to address market challenges, including global expansion, flexible trade arrangements, customer pricing strategies, and continuous cost reduction through technological innovation [2] - The demand for peptide raw materials is significant, and the company has established strategic partnerships with global clients, expanding beyond traditional markets to include Latin America and the Middle East [2] - The platform for imported chronic disease medications is experiencing strong supply and demand, with stable supply of original imported drugs and measures in place to ensure price stability [3]

China Chengxin International Credit Rating Co.,Ltd. [2025]152 中诚信国际关于终止江苏诺泰澳赛诺生物制药股份有限公司 主体和相关债项信用评级的公告 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"诺泰生物"或"公司"） 发行的"诺泰转债"由中诚信国际信用评级有限责任公司（以下简称"中诚信国 际"）进行相关评级工作。2024 年 5 月 27 日，中诚信国际对公司及上述债券进 行定期跟踪评级，维持诺泰生物主体信用等级为 A + k，评级展望为稳定，维持"诺 泰转债"债项信用等级为 A + k。 近日，公司发布公告称，根据《江苏诺泰澳赛诺生物制药股份有限公司向不 特定对象发行可转换公司债券募集说明书》的约定，已触发"诺泰转债"的有条 件赎回条款，且经公司董事会审议，公司决定行使"诺泰转债"的提前赎回权， 对赎回登记日（即 2025 年 4 月 24 日）登记在册的"诺泰转债"全部赎回。截至 2025 年 4 月 24 日（赎回登记日收市后），累计共有 429,956,000 元"诺泰转债" 已转换为公司股本，累计转股数为 10,168,365 股，占"诺泰 ...

关于江苏诺泰澳赛诺生物制药股份有限公司 2024 年度持续督导报告书 南京证券股份有限公司 根据《证券发行上市保荐业务管理办法》和《上海证券交易所上市公司自律监 管指引第 11 号——持续督导》等有关法律、法规的要求，南京证券股份有限公司 （以下简称"南京证券"或"保荐机构"）作为江苏诺泰澳赛诺生物制药股份有限 公司（以下简称"诺泰生物"或"公司"）持续督导工作的保荐机构，负责诺泰生 物上市后的持续督导工作，并出具本持续督导报告书。 一、持续督导工作情况 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针 | 保荐机构已建立并有效执行了 | | | | 持续督导制度，并制定了相应的 | | | 对具体的持续督导工作制定相应的工作计划。 | 工作计划。 | | 2 | 根据中国证监会相关规定，在持续督导工作开 | 保荐机构已与诺泰生物签订保 | | | 始前，与上市公司或相关当事人签署持续督导 | 荐协议，该协议明确了双方在持 | | | 协议，明确双方在持续督导期间的权利义务， | 续督导期间的权利和义务，并报 | | | ...

Macro Strategy - The core viewpoint emphasizes the need for more proactive macro policies to stabilize the economy amid external shocks, with a focus on timely implementation of existing policies and introduction of new incremental policies [2][3] - The April Politburo meeting acknowledged the economic recovery but highlighted the necessity to solidify this foundation, especially in light of increasing external pressures [1][2] Fixed Income - The fixed income market is expected to remain in a narrow fluctuation pattern, with key observation points in May regarding potential reserve requirement ratio cuts [3][4] - The issuance of green bonds decreased significantly, with only 14 new bonds issued totaling approximately 10.87 billion yuan, while trading volume increased to 56.2 billion yuan [4] Company Analysis Arrow Home (001322) - The company faced demand pressure, with revenue expected to decline year-on-year in the first half of 2024, but a recovery is anticipated in the second half due to national subsidy policies [7] - Revenue from retail channels decreased due to intensified competition, while the home decoration channel showed growth [7] - The company is adjusting its strategy to focus on retail channels and enhance product strength and brand marketing [7] Nuotai Bio (688076) - The company reported a significant revenue increase of 57.21% in 2024, driven by the growth of peptide APIs [8] - The custom product segment also showed strong growth, with a notable order from a major European pharmaceutical company [8] - The forecast for net profit remains optimistic, with expected growth in the coming years [9] Taiji Group (600129) - The company experienced a substantial decline in revenue and net profit in Q1 2025, but there are signs of improvement compared to Q4 2024 [10] - The profit forecast for 2025-2026 has been adjusted downward due to ongoing market challenges [10] Guizhou Sanli (603439) - The company achieved a revenue increase of 31.16% in 2024, but faced a decline in net profit [11] - The forecast for net profit has been adjusted downward for 2025-2026, reflecting short-term pressures [11] National Grid Yingda (600517) - The company is pursuing dual development in finance and manufacturing, with a stable performance expected in 2024 [25] - The profit forecast for 2025-2027 has been slightly adjusted, but the long-term growth potential remains positive [25] Hengli Petrochemical (600346) - The company reported stable profitability despite industry competition, with a focus on optimizing operations and maintaining high dividend payouts [26][27] - The profit forecast for 2025-2026 has been adjusted downward, but the company continues to show growth potential [27] National Securities (600109) - The company reported a slight decline in revenue for 2024 but showed strong growth in Q1 2025 [28] - The profit forecast for 2025-2027 indicates a steady increase, supported by market reforms and economic recovery [28] Cambrian (688256) - The company achieved significant revenue growth in Q1 2025, driven by strong contributions from its largest customer [29] - The outlook for 2025 remains positive, with expectations for continued revenue growth and improved profitability [29] Giant Network (002558) - The company is actively expanding its AI capabilities, with a positive outlook for revenue growth in the coming years [30][31] - The profit forecast for 2025-2027 has been adjusted upward, reflecting a strong pipeline of new games [31]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology field and AI medical investment opportunities [3][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) [3][8]. - The upcoming ASCO conference is highlighted as a significant event for domestic innovative drug companies, with over 70 oral presentations and more than 10 major studies expected [3][4]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry, aiming for significant advancements by 2027 and full coverage by 2030 [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16% from April 21 to April 25, outperforming the Wind All A index and the CSI 300 index [3][8]. - Notable performers included medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][9]. - Individual stock performances showed significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, Kangfang Bio announced FDA approval for its drug Anike for the treatment of recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Bio also reported the approval of its PD-1/VEGF bispecific antibody for first-line treatment of specific lung cancer types [13]. - The digital transformation plan for the pharmaceutical industry aims to enhance competitiveness and quality management through AI and data integration by 2030 [3][4].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2] Core Viewpoints - The report anticipates a recovery in the pharmaceutical sector in Q2 2025, with a focus on innovative drugs, AI healthcare, and consumer healthcare [2][17] - The report highlights that 52% of pharmaceutical companies have disclosed their Q1 2025 performance, with 35% showing growth in both revenue and net profit [13][17] - The report suggests that the pharmaceutical sector is expected to experience performance recovery due to the gradual digestion of policy impacts and the revival of both inpatient and outpatient markets [17] Summary by Sections 1. Industry Overview - The pharmaceutical and biotechnology sector's weekly return was 1.16%, ranking 15th among 31 primary sub-industry indices [11] - The medical services sub-sector had the highest weekly increase of 3.38%, while the bioproducts sub-sector saw a decline of 0.93% [11][31] 2. Performance and Valuation of the Pharmaceutical Sector - The pharmaceutical industry index's current PE (TTM) is 26.25 times, which is below the historical average of 31.15 times [21][24] - The report indicates that the pharmaceutical sector's performance over the last month was -2.19%, with a relative performance of 1.51% compared to the CSI 300 index [27] 3. Market Tracking - The report notes that the chemical pharmaceutical sub-sector had the highest one-year increase of 12.82%, while the pharmaceutical commercial sub-sector experienced the largest decline of 14.33% [34] - The report also highlights that the medical services sub-sector had the highest weekly increase of 3.38% [40] 4. Industry and Company Dynamics - The report discusses recent policy developments, including the implementation plan for the digital transformation of the pharmaceutical industry from 2025 to 2030, aiming for comprehensive digital transformation by 2030 [12][49] - It also mentions significant company announcements, such as clinical trial approvals for various innovative drugs [51]